SCHEMBL26225680

SCHEMBL26225680

CC(C)c1ccc2c(c1)n(C)c(=N)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
BRPF1 P55201 2/20 0.40
TRIM24 O15164 1/20 0.40
BRD1 O95696 1/20 0.40
TRPA1 O75762 1/20 0.39
PTGS1 P23219 1/20 0.39
CACNA1C Q13936 1/20 0.39
BRD4 O60885 1/20 0.36
CXCR3 P49682 1/20 0.36
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PARP15 Q460N3 1/20 0.35
PARP10 Q53GL7 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
HTT P42858 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13757706 0.80 POLB (0.50) LMNABRPF1TRIM24BRD1BRD4
SCHEMBL13340940 0.80 BRPF1 (0.57) LMNABRPF1TRIM24BRD1BRD4
SCHEMBL12083594 0.72 RORA (0.46) LMNABRPF1TRIM24BRD1TRPA1
SCHEMBL12611289 0.72 KIF11 (0.41) LMNATRPA1PTGS1CACNA1CPARP15
SCHEMBL25446875 0.72 MAPK14 (0.47) BRPF1TRIM24BRD1BRD4SMN1; SMN2
SCHEMBL27300521 0.72 HPD (0.50) BRPF1TRIM24BRD1BRD4POLB
SCHEMBL22822495 0.68 ALDH1A1 (0.45) BRPF1TRIM24BRD1BRD4POLB
SCHEMBL24052039 0.68 HTT (0.52) CXCR3SMN1; SMN2HTT
SCHEMBL23171258 0.67 LMNA (0.39) LMNABRPF1TRIM24BRD1TRPA1
SCHEMBL13677503 0.67 HTR7 (0.38) LMNATRPA1PTGS1CACNA1CPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 LMNA 4144/4885BRPF1 1548/4885TRIM24 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.